PTPN13/PTPL1 Recombinant Protein Antigen

• Reactivity: Hu
• Applications: AC

PTPN13/PTPL1 Recombinant Protein Antigen Summary

• Description: A recombinant protein antigen with a N-terminal His6-ABP tag corresponding to human PTPN13/PTPL1
  
  

  Source: E.coli

  Amino Acid Sequence: STPVHLTNEMKNYMKKSSYMQDSAIDSSSKDHHWSRGTLRHISENSFGPSGGLREGSLSSQDSRTESASLSQSQVNGFFASHLGDQTWQESQHGSPSPSVISKATE

  Fusion Tag: N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G)

  This product is intended to be used as a blocking antigen for antibody competition assays. Any other use of this antigen is done at the risk of the user. The use of this product for commercial production is strictly prohibited. Please contact technical support if you have any questions.

• Source: E. coli
• Protein/Peptide Type: Recombinant Protein Antigen
• Gene: PTPN13
• Purity: >80% by SDS-PAGE and Coomassie blue staining

Applications/Dilutions

• Dilutions:
  • Antibody Competition 10-100 molar excess
• Application Notes: This recombinant antigen is only intended to be used as a blocking agent to confirm antibody specificity with the corresponding antibody, catalog number NBP3-17189. It is purified by IMAC chromatography, and the expected concentration is greater than 0.5 mg/ml.For current lot information, including availability, please contact our technical support team click nb-technical@bio-techne.com
• Theoretical MW: 29 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS and 1M Urea, pH 7.4.
• Preservative: No Preservative
• Purity: >80% by SDS-PAGE and Coomassie blue staining

Alternate Names for PTPN13/PTPL1 Recombinant Protein Antigen

• EAP-1
• FAP-1
• hPTPE1
• PNP1
• protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associatedphosphatase)
• protein-tyrosine phosphatase 1, Fas-associated
• PTP1E
• PTP1EDKFZp686J1497
• PTP-BAS
• PTP-BASEC 3.1.3.48
• PTP-BL
• PTP-E1
• PTPL1
• PTPL1nonreceptor type 13
• PTPLE
• PTPN13
• tyrosine-protein phosphatase non-receptor type 13

Background

FAP-1 (also known as Fas-associated phosphatase-1, PTPN13, PTP-BAS, hPTPIE, and PTPL1) is a member of the protein tyrosine phosphatase (PTP) family (reviewed in Meinhold-Heerlein et al, 2001; Savaskan et al, 2005; Foehr et al, 2005; and Ivanov et al, 2006). PTPs are enzymes that catalyze the removal of a phosphate group attached to a tyrosine residue. Most intracellular signaling involves reversible phosphorylation events; therefore, PTPs are central to the dynamic regulation of signaling cascades that underlie cell functions. For example, PTPs play key roles in regulating cell growth, differentiation, proliferation, inflammation, and oncogenic transformation. PTPs are emerging as a promising class of signaling targets for diseases such as cancer, neurodegeneration, diabetes, and inflammation. A key challenge is to identify specific PTPs that are invovled in a disease process and develop therapeutics to modulate the PTP. FAP-1 phosphatase is thought to be important in the Fas signaling pathway. FAP-1 binds to the cytosolic tail of the Fas receptor (Apo1, CD95) and inhibits Fas-induced apoptosis. Increased FAP-1 protein levels in some tumor cell lines and tumor tissues correlates with resistance to Fas-mediated apoptosis. In general, FAP-1 expression has been found to be highest in cell lines and tissues that are relatively resistant to Fas-mediated apoptosis. Gene transfer-mediated elevations in FAP-1 partially abolished Fas-induced apoptosis in a T cell line which is consistent with an inhibitory effect of FAP-1 on Fas signal transductions. Additionally, FAP-1 expression correlates with Fas resistant in ovarian cancer cell lines and FAP-1 is commonly expression in ovarian cancers. Human Fas has a putative consensus tyrosine phosphorylation site (Tyrosine 275) suggesting that Fas surface expression or signaling may be regulated by phosphorylation. FAP-1 has been shown to directly bind to Fas and may dephosphorylate Fas as part of the down regulation of the apoptotic pathway. It is thought that development of therapeutics to inhibit FAP-1 may increase the ability of tumor cells with upregulated FAP-1 to undergo apoptosis. FAP-1 is a large approx. 270 kDa protein. Multiple alternatively spliced FAP-1 transcript variants which encode distinct proteins have been reported, including shorter forms. Please see Application Notes section for additional details on FAP-1 isoforms.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: PTPN13